114 related articles for article (PubMed ID: 9377119)
1. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group.
Katzenstein TL; Eugen-Olsen J; Hofmann B; Benfield T; Pedersen C; Iversen AK; Sørensen AM; Garred P; Koppelhus U; Svejgaard A; Gerstoft J
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):10-4. PubMed ID: 9377119
[TBL] [Abstract][Full Text] [Related]
2. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
Bratt G; Leandersson AC; Albert J; Sandström E; Wahren B
AIDS; 1998 May; 12(7):729-36. PubMed ID: 9619804
[TBL] [Abstract][Full Text] [Related]
3. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.
Walli R; Reinhart B; Luckow B; Lederer E; Loch O; Malo A; Wank R; Schlöndorff D; Goebel FD
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):229-33. PubMed ID: 9665499
[TBL] [Abstract][Full Text] [Related]
4. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
5. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
[TBL] [Abstract][Full Text] [Related]
6. Association between CCR5 genotype and the clinical course of HIV-1 infection.
de Roda Husman AM; Koot M; Cornelissen M; Keet IP; Brouwer M; Broersen SM; Bakker M; Roos MT; Prins M; de Wolf F; Coutinho RA; Miedema F; Goudsmit J; Schuitemaker H
Ann Intern Med; 1997 Nov; 127(10):882-90. PubMed ID: 9382366
[TBL] [Abstract][Full Text] [Related]
7. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.
Henrich TJ; Hanhauser E; Hu Z; Stellbrink HJ; Noah C; Martin JN; Deeks SG; Kuritzkes DR; Pereyra F
AIDS; 2015 May; 29(8):867-76. PubMed ID: 25730507
[TBL] [Abstract][Full Text] [Related]
8. Relationship between CCR5
Martínez-Bonet M; González-Serna A; Clemente MI; Morón-López S; Díaz L; Navarro M; Puertas MC; Leal M; Ruiz-Mateos E; Martinez-Picado J; Muñoz-Fernández MA
Clin Microbiol Infect; 2017 May; 23(5):318-324. PubMed ID: 28042001
[TBL] [Abstract][Full Text] [Related]
9. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
Hütter G; Nowak D; Mossner M; Ganepola S; Müssig A; Allers K; Schneider T; Hofmann J; Kücherer C; Blau O; Blau IW; Hofmann WK; Thiel E
N Engl J Med; 2009 Feb; 360(7):692-8. PubMed ID: 19213682
[TBL] [Abstract][Full Text] [Related]
10. Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study.
Daar ES; Lynn H; Donfield S; Gomperts E; Hilgartner MW; Hoots K; Chernoff D; Winkler C; O'Brien SJ
J Acquir Immune Defic Syndr; 1999 Aug; 21(4):317-25. PubMed ID: 10428111
[TBL] [Abstract][Full Text] [Related]
11. Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene.
Kupfer B; Kaiser R; Brackmann HH; Effenberger W; Rockstroh JK; Matz B; Schneweis KE
AIDS; 1999 Jun; 13(9):1025-8. PubMed ID: 10397531
[TBL] [Abstract][Full Text] [Related]
12. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
[TBL] [Abstract][Full Text] [Related]
13. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
Lathey JL; Tierney C; Chang SY; D'Aquila RT; Bettendorf DM; Alexander HC; Santini CD; Hughes AM; Barroga CF; Spector SA; Landes JE; Hammer SM; Katzenstein DA
J Infect Dis; 2001 Dec; 184(11):1402-11. PubMed ID: 11709782
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort.
Eugen-Olsen J; Iversen AK; Benfield TL; Koppelhus U; Garred P
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):110-6. PubMed ID: 9637575
[TBL] [Abstract][Full Text] [Related]
15. Causal pathways for CCR5 genotype and HIV progression.
Taylor JM; Wang Y; Ahdieh L; Chmiel JS; Detels R; Giorgi JV; Kaslow R; Kingsley L; Margolick J
J Acquir Immune Defic Syndr; 2000 Feb; 23(2):160-71. PubMed ID: 10737431
[TBL] [Abstract][Full Text] [Related]
16. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression.
Paxton WA; Kang S; Koup RA
AIDS Res Hum Retroviruses; 1998 Apr; 14 Suppl 1():S89-92. PubMed ID: 9581891
[TBL] [Abstract][Full Text] [Related]
17. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
Laurichesse JJ; Taieb A; Capoulade-Metay C; Katlama C; Villes V; Drobacheff-Thiebaud MC; Raffi F; Chêne G; Theodorou I; Leport C;
HIV Med; 2010 Apr; 11(4):239-44. PubMed ID: 20050936
[TBL] [Abstract][Full Text] [Related]
18. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic expressions of CCR5-delta32/delta32 homozygosity.
Nguyêñ GT; Carrington M; Beeler JA; Dean M; Aledort LM; Blatt PM; Cohen AR; DiMichele D; Eyster ME; Kessler CM; Konkle B; Leissinger C; Luban N; O'Brien SJ; Goedert JJ; O'Brien TR
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):75-82. PubMed ID: 10534150
[TBL] [Abstract][Full Text] [Related]
20. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.
Stewart GJ; Ashton LJ; Biti RA; Ffrench RA; Bennetts BH; Newcombe NR; Benson EM; Carr A; Cooper DA; Kaldor JM
AIDS; 1997 Dec; 11(15):1833-8. PubMed ID: 9412701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
